Louis George Lange

US Patent:

20090111826, Apr 30, 2009

Filed:

Feb 13, 2008

Appl. No.:

12/030468

Inventors:

Louis Lange - Portola Valley CA, US
Marcus Jerling - Bromma, SE
Andrew Wolff - San Francisco CA, US

International Classification:

A61K 31/495
A61P 9/00

US Classification:

51425212

Abstract:

Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.

US Patent:

20090312340, Dec 17, 2009

Filed:

Feb 12, 2009

Appl. No.:

12/370442

Inventors:

Whedy Wang - Portola Valley CA, US
Ewa Prokopczuk - Danville CA, US
Luiz Belardinelli - Palo Alto CA, US
Louis Lange - Palo Alto CA, US
Markus Jerling - Bromma, SE
Andrew Wolff - San Francisco CA, US

International Classification:

A61K 31/4965
A61P 9/06

US Classification:

51425212

Abstract:

Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.

US Patent:

20100035890, Feb 11, 2010

Filed:

Oct 15, 2009

Appl. No.:

12/579956

Inventors:

Louis Lange - Palo Alto CA, US
Markus Jerling - Bromma, SE
Andrew Wolff - San Francisco CA, US

Assignee:

Gilead Palo Alto, Inc. - Foster City CA

International Classification:

A61K 31/4965
A61P 9/00

US Classification:

51425212

Abstract:

Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.

US Patent:

55213030, May 28, 1996

Filed:

Oct 13, 1994

Appl. No.:

8/322782

Inventors:

Louis G. Lange - Portola Valley CA
Curtis A. Spilburg - Sunnyvale CA
Dayton T. Reardan - Excelsior MN

Assignee:

CV Therapeutics, Inc. - Palo Alto CA

International Classification:

C07H 106
C08B 300

US Classification:

536 59

Abstract:

This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

US Patent:

58695370, Feb 9, 1999

Filed:

May 9, 1997

Appl. No.:

8/854145

Inventors:

George F. Schreiner - Los Altos CA
Louis G. Lange - Portola Valley CA

Assignee:

CV Therapeutics - Palo Alto CA

International Classification:

A61K 3108

US Classification:

514722

Abstract:

This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.

US Patent:

56634501, Sep 2, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/470974

Inventors:

George F. Schreiner - Los Altos CA
Louis G. Lange - Portola Valley CA

Assignee:

CV Therapeutics - Palo Alto CA

International Classification:

C07C 4917
C07C 49175

US Classification:

568415

Abstract:

This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.

US Patent:

54320585, Jul 11, 1995

Filed:

Sep 30, 1992

Appl. No.:

7/954864

Inventors:

Louis G. Lange - Portola Valley CA
Richard E. Ostlund - Ladue MO
Matthew S. Bosner - Chesterfield MO

International Classification:

C12Q 160
G01N 3100
A01N 4304

US Classification:

435 11

Abstract:

This invention is a method for measuring the ability of a human to absorb cholesterol. The method uses two different cholesterol tracers, the first injected into the blood stream and the second ingested by the human subject. After a waiting period a blood sample is taken from the human subject and analyzed to determine percent cholesterol absorption based on the actual amounts of the two naturally occurring, metabolically stable cholesterol tracers in the blood. The method of this invention is useful in identifying human subjects as high cholesterol absorbers and thereafter administering therapeutic agents to the subject that inhibit the absorption of cholesterol.

US Patent:

20210220376, Jul 22, 2021

Filed:

Apr 7, 2021

Appl. No.:

17/224902

Inventors:

- Palo Alto CA, US
Louis G. Lange - Palo Alto CA, US
Peter M. Strumph - San Francisco CA, US

Assignee:

Amygdala Neurosciences, Inc. - Palo Alto CA

International Classification:

A61K 31/675
A61K 31/4418
A61K 31/352
A61P 25/32

Abstract:

Disclosed herein are methods of treating addiction to a dopamine-producing agent (e.g., amphetamine, cocaine, nicotine, opioids) in patient populations that do not exclude alcohol consumption during treatment. The methods generally comprise administering to the patient a therapeutically effective amount of an aldehyde dehydrogenase-2 (ALDH-2) inhibitor, such as compound (1)